Objective:

To evaluate treatment outcomes and prognostic factors influencing overall survival (OS) and intracranial progression-free survival (iPFS) in patients with EGFR-mutated NSCLC and brain metastases treated with radiotherapy and EGFR-TKIs.

Approach:

Key Findings:

• 135 patients included; 70 received early RT, 65 received delayed RT.
• EGFR mutation subtype and extent of metastases associated with OS (p < 0.05).
• Mutation subtype and timing of RT linked to iPFS.
• Early RT independently improved iPFS (14.6 vs. 10.4 months, p = 0.010).
• Median OS superior in patients with exon 19 deletions compared to exon 21 L858R mutations (37.5 vs. 25.1 months, p = 0.009).

Interpretation:

Patients with EGFR-mutated NSCLC and brain metastases showed varying outcomes based on the timing of radiotherapy and mutation subtype.

Limitations:

• Retrospective design may introduce selection bias.
• Single-institution study limits generalizability.

Conclusion:

Early RT in conjunction with EGFR-TKIs can improve intracranial outcomes in patients with EGFR-mutated NSCLC and brain metastases.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.